Physician profile
Jennifer Botkin
NPI 1245225283
$2,533.76
in general payments reported to CMS, 2019-2025
28 companies · $429 in 2025
The $429 reported for 2025 was more than what 91% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $327 · 2020: $150 · 2021: $188 · 2022: $341 · 2023: $384 · 2024: $715 · 2025: $429.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,528.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,527.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $422.00 | 2021-2025 | Qelbree, Qelbree |
| Corium, LLC | $318.14 | 2022-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $292.58 | 2019-2024 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $158.19 | 2020-2022 | |
| Cranial Technologies, INC | $144.16 | 2019-2025 | Doc Band |
| Pfizer INC. | $135.15 | 2019-2025 | |
| Neos Therapeutics, LP | $128.19 | 2019-2023 | Adzenys Xr-Odt |
| Glaxosmithkline, LLC. | $118.34 | 2019-2024 | Pediarix, Bexsero, Rotarix |
| Ars Pharmaceuticals Operations, INC. | $98.80 | 2025 | Neffy |
| Tris Pharma INC | $91.59 | 2019-2024 | Dyanavel Xr |
| Noven Therapeutics, LLC | $72.99 | 2023-2025 | Xelstrym |
| Merck Sharp & Dohme LLC | $69.31 | 2023-2025 | Gardasil 9, Vaxneuvance, Gardasil |
| Adlon Therapeutics L.P. | $61.53 | 2019-2021 | |
| Ultragenyx Pharmaceutical INC. | $60.63 | 2021-2024 | Crysvita |
| Sanofi Pasteur INC. | $54.93 | 2023-2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $53.16 | 2024 | |
| Kaleo, INC. | $52.45 | 2019-2020 | |
| Verrica Pharmaceuticals INC. | $35.38 | 2023-2025 | Ycanth |
| Collegium Pharmaceutical, INC. | $31.21 | 2025 | Jornay Pm |
| Shire North American Group INC | $20.44 | 2019 | |
| Dermira, INC. | $17.18 | 2020 | |
| Lnhc, INC | $16.51 | 2025 | Zelsuvmi |
| Ironwood Pharmaceuticals, INC | $15.77 | 2024 | |
| Sobi, INC | $14.59 | 2019 | |
| Rhodes Pharmaceuticals L.P. | $14.54 | 2019 | |
| Vertical Pharmaceuticals, LLC | $14.34 | 2025 | Relexxii |
| Sarepta Therapeutics, INC. | $13.44 | 2019 | |
| Romark Laboratories, Lc | $8.22 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Botkin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.